AU2001269688A1 - Combination containing an antifolate and methylmalonic acid lowering agent - Google Patents

Combination containing an antifolate and methylmalonic acid lowering agent

Info

Publication number
AU2001269688A1
AU2001269688A1 AU2001269688A AU6968801A AU2001269688A1 AU 2001269688 A1 AU2001269688 A1 AU 2001269688A1 AU 2001269688 A AU2001269688 A AU 2001269688A AU 6968801 A AU6968801 A AU 6968801A AU 2001269688 A1 AU2001269688 A1 AU 2001269688A1
Authority
AU
Australia
Prior art keywords
antifolate
lowering agent
methylmalonic acid
acid lowering
combination containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001269688A
Other languages
English (en)
Inventor
Clet Niyikiza
Paolo Paoletti
James Jacob Rusthoven
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27396105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001269688(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2001269688A1 publication Critical patent/AU2001269688A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2001269688A 2000-06-30 2001-06-15 Combination containing an antifolate and methylmalonic acid lowering agent Abandoned AU2001269688A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US21531000P 2000-06-30 2000-06-30
US60/215,310 2000-06-30
US23585900P 2000-09-27 2000-09-27
US60/235,859 2000-09-27
US28444801P 2001-04-18 2001-04-18
US60/284,448 2001-04-18
PCT/US2001/014860 WO2002002093A2 (en) 2000-06-30 2001-06-15 Combination containing an antifolate and methylmalonic acid lowering agent

Publications (1)

Publication Number Publication Date
AU2001269688A1 true AU2001269688A1 (en) 2002-01-14

Family

ID=27396105

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001269688A Abandoned AU2001269688A1 (en) 2000-06-30 2001-06-15 Combination containing an antifolate and methylmalonic acid lowering agent

Country Status (11)

Country Link
US (4) US7053065B2 (enExample)
EP (1) EP1313508B1 (enExample)
JP (7) JP5102928B2 (enExample)
AT (1) ATE359823T1 (enExample)
AU (1) AU2001269688A1 (enExample)
CY (1) CY1107649T1 (enExample)
DE (1) DE60127970T2 (enExample)
DK (1) DK1313508T5 (enExample)
ES (1) ES2284660T3 (enExample)
PT (1) PT1313508E (enExample)
WO (1) WO2002002093A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60127970T2 (de) * 2000-06-30 2007-12-20 Eli Lilly And Co., Indianapolis Zusammensetzung, welche ein antifolate und ein methylmalonsäuresenkendes mittel enthält
JP5129122B2 (ja) 2005-04-26 2013-01-23 トリオン ファーマ ゲーエムベーハー 癌治療のための抗体およびグルココルチコイドの組み合わせ
CA2637069A1 (en) * 2006-01-12 2007-07-19 Novartis Ag Combination of mtor inhibitor and antipolate compound
WO2010021843A1 (en) * 2008-08-20 2010-02-25 Eli Lilly And Company Use of antifolates in patients with detectable levels of tff-1 for the cancer treatment
WO2010138955A2 (en) 2009-05-29 2010-12-02 University Of Florida Research Foundation, Inc. Methods and compositions for treating neoplasia
JP5899241B2 (ja) 2010-12-21 2016-04-06 ネクター セラピューティクス ペメトレキセドベースの化合物のマルチアームポリマープロドラッグコンジュゲート
SI2854768T1 (sl) 2012-05-30 2017-08-31 Fresenius Kabi Oncology Limited Farmacevtski sestavki pemetrekseda
RU2016151390A (ru) * 2014-06-04 2018-07-17 Томас Хелледайс Стифтелсе Фёр Медисинск Форскнинг Ингибиторы мтн1 для лечения воспалительных и аутоиммунных заболеваний
CA3177726A1 (en) 2015-05-21 2016-11-24 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
AU2016298439B2 (en) * 2015-07-30 2018-11-08 Expression Pathology, Inc. Quantifying FR-alpha and GART proteins for optimal cancer therapy
FI3386546T3 (fi) * 2015-12-07 2024-12-05 General Oncology Inc Yhdistelmä metastaattisen syövän tehokkaaseen hoitoon potilailla
US20180236098A1 (en) 2016-08-12 2018-08-23 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
AU2017308159B2 (en) 2016-08-12 2023-08-10 L.E.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP4046989A1 (en) 2017-01-09 2022-08-24 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
JP7487107B2 (ja) 2018-02-07 2024-05-20 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化葉酸代謝拮抗薬およびその使用
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
CN111954531A (zh) 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 α聚谷氨酸化培美曲塞及其用途
CN111954530A (zh) 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 γ聚谷氨酸化培美曲塞及其用途
EP3749319A4 (en) 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC TETRAHYDROFOLATES ALPHA POLYGLUTAMATE AND THEIR USES
CA3090384A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
EP3749316A4 (en) 2018-02-07 2021-10-27 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATED PRALATREXATE AND USES THEREOF
CA3090391A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated raltitrexed and uses thereof
CA3090389A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
EP3749312A4 (en) 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATED LOMETREXOLE AND USES THEREOF
WO2019157125A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated methotrexate and uses thereof
CA3090875A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
WO2019160736A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
CA3090943A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
US12048766B2 (en) 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
WO2019160733A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated methotrexate and uses thereof
WO2023177894A1 (en) 2022-03-18 2023-09-21 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and an antimetabolite agent
WO2025247952A1 (en) * 2024-05-30 2025-12-04 Université De Fribourg Inhibition of cyanide overproduction for the therapy of down syndrome and nonketotic hyperglycinemia

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US216350A (en) * 1879-06-10 Improvement in car-replacers
US225030A (en) * 1880-03-02 Rotary engine
US2920015A (en) * 1957-08-27 1960-01-05 Armour & Co Long-acting vitamin b12
CH588505A5 (enExample) * 1972-06-08 1977-06-15 Research Corp
US5563126A (en) * 1986-11-20 1996-10-08 Metabolite Laboratories Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
JP2962755B2 (ja) * 1989-02-28 1999-10-12 帝人株式会社 新規ビタミンｂ▲下１▼▲下２▼誘導体、その製造方法並びにその用途
US5405839A (en) * 1989-02-28 1995-04-11 Teijin Limited Vitamin B12 derivative, preparation process thereof, and use thereof
KR0162654B1 (ko) * 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
DK0505640T4 (da) * 1991-03-29 2002-12-16 Lilly Co Eli Forbedret terapeutisk metode
JPH05163160A (ja) * 1991-12-13 1993-06-29 Snow Brand Milk Prod Co Ltd 免疫低下に伴う感染症の予防及び治療用栄養剤
US6207651B1 (en) * 1996-08-02 2001-03-27 Metabolite Laboratories Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
DE69528523T2 (de) 1994-04-08 2003-06-12 Receptagen Corp., Edmonds Rezeptor modulierendes mitteln und entsprechendes verfahren
WO1996012181A1 (en) * 1994-10-12 1996-04-25 Research & Diagnostics Systems, Inc. Reticulocyte assay control
DE60127970T2 (de) * 2000-06-30 2007-12-20 Eli Lilly And Co., Indianapolis Zusammensetzung, welche ein antifolate und ein methylmalonsäuresenkendes mittel enthält
US20040005311A1 (en) * 2001-07-20 2004-01-08 Pitman Bradford D. Dietary supplement compositions

Also Published As

Publication number Publication date
JP2014005304A (ja) 2014-01-16
DK1313508T3 (da) 2007-08-06
US20060079480A1 (en) 2006-04-13
CY1107649T1 (el) 2013-04-18
US7053065B2 (en) 2006-05-30
JP2018197265A (ja) 2018-12-13
EP1313508B1 (en) 2007-04-18
DK1313508T5 (da) 2017-03-20
WO2002002093A3 (en) 2003-02-06
EP1313508A2 (en) 2003-05-28
PT1313508E (pt) 2007-06-21
US20030212038A1 (en) 2003-11-13
US20100210583A1 (en) 2010-08-19
ATE359823T1 (de) 2007-05-15
US20080032948A1 (en) 2008-02-07
JP2020117536A (ja) 2020-08-06
JP5469706B2 (ja) 2014-04-16
WO2002002093A2 (en) 2002-01-10
JP2012180381A (ja) 2012-09-20
JP5102928B2 (ja) 2012-12-19
JP2004501964A (ja) 2004-01-22
US7772209B2 (en) 2010-08-10
JP2017019852A (ja) 2017-01-26
ES2284660T3 (es) 2007-11-16
JP2015178501A (ja) 2015-10-08
DE60127970D1 (de) 2007-05-31
DE60127970T2 (de) 2007-12-20

Similar Documents

Publication Publication Date Title
AU2001269688A1 (en) Combination containing an antifolate and methylmalonic acid lowering agent
WO2001068138A3 (en) Intradermal-penetration agents for topical local anesthetic administration
AU2002245302A1 (en) Methods of using and compositions comprising sibutramine metabolites optionally in combination with other pharmacologically active compounds
BR9812289A (pt) Combinação de tampão catamenial e dispositivo de inserção e processo de produção
AU3104301A (en) Compositions and methods to effect the release profile in the transdermal administration of active agents
AU2002230642A1 (en) Proton generating catheters and methods for their use
WO2002005800A8 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
WO2001062290A3 (en) Methods and compositions for improving sleep
AU2001286578A1 (en) Topical antioxidant having vitamin c and method of combination with topical agent by user
WO2000011971A3 (en) Fiber and vitamin-fortified beverage
MXPA03002207A (es) Derivados de acido 2-amino-2-alquil-5-heptenoico y -heptinoico utiles como inhibidores de la oxido nitrico sintasa.
AU5905400A (en) Methods and compositions for delivery and retention of active agents to lymph nodes
AU7914600A (en) The use of baclofen in the treatment of alcohol withdrawal syndrome and to promote alcohol abstinence in alcoholics
IS6581A (is) Samsetning sem eykur hreyfanleika
WO2001085188A3 (en) Use of echinacea as a hematinic agent
WO2001043748A3 (en) Implant composition containing melengestrol acetate and trenbolone acetate
ZA200301459B (en) Infusion of ciprofloxacin having reduced acid content and being stable in storage.
AU4874301A (en) Medicinal compositions containing camptothecin derivative and ph regulating agent
AU4193800A (en) Use of tagatose to enhance key blood factors
MXPA03002211A (es) Derivados de acido 2-amino-2-alquil-4-heptenoico y heptinoico utiles como inhibidores de la oxido nitrico sintasa.
WO2002022558A3 (en) 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
YU79802A (sh) Formulacija sa aktivnošću mobilizacije
AU7370798A (en) Compositions and methods of therapy for igf-i-responsive conditions
SI1313508T1 (sl) Sestava, ki vsebuje antifolat in sredstvo za zniĹľevanje metilmalonske kisline
AU2002243652A1 (en) Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds